Corcept Therapeutics Incorporated (CORT) Earnings Call Transcripts
Corcept Therapeutics Incorporated's Latest Earnings Call - Q1 FY2026
In the first quarter of 2026, Corcept Therapeutics reported revenue of $164.9 million, up from $157.2 million year-over-year, and a net loss of $31.8 million compared to a net income of $20.5 million in the prior year. The company raised its full-year revenue guidance to a range of $950 million to $1.05 billion, reflecting strong demand for its medications and the recent FDA approval of Lifyorli. Management highlighted the ongoing growth in their endocrinology business driven by increased awareness of hypercortisolism and the successful launch of Lifyorli in oncology, which is expected to exceed $1 billion in annual revenue by the end of the decade.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $164.9 million (beat) |
| Net Loss | $31.8 million (miss) |
| 2026 Revenue Guidance | $950 million to $1.05 billion (positive) |
| New Prescriptions | 200+ physicians (positive) |
| Cash and Investments | $515 million (null) |
| Expected Cushing's Syndrome Revenue | $2 billion (positive) |
Guidance from management
Corcept raised its 2026 revenue guidance to a range of $950 million to $1.05 billion, indicating strong growth expectations driven by both endocrinology and oncology segments.
What management said
Thank you, Roberto. And let me introduce a person who hasn't spoken yet, Bill Guyer, who runs all of our -- our Chief Development Officer, who runs all of our development activities to make a comment or 2 about nenocorilant.
Thank you very much. Well, this concludes our call. Thank you very much for listening for the questions. I think it's a very, very exciting time for the company. We're really pleased with what we're seeing both in the endocrinology and on the oncology side. Please look at our press release for all of the things which are going on in development. It really is wonderful to be able to see us really bring forward towards...
What analysts pressed on
Analysts expressed concerns over the significant net loss reported in Q1 2026, questioning the sustainability of profitability amidst rising revenues. There were also inquiries regarding the scalability of their specialty pharmacy partnerships to handle increased prescription volumes.
Main topics on the call
- Revenue Growth Acceleration — Corcept's revenue increased to $164.9 million in Q1 2026, up from $157.2 million in Q1 2025. Management noted, "demand for our medications continues to increase," indicating strong future revenue potential.
- Increased Guidance — The company raised its 2026 revenue guidance to $950 million to $1.05 billion, reflecting confidence in both the endocrinology and oncology segments. CFO Atabak Mokari stated, "we are confidently raising our guidance ran...
- Launch of Lifyorli — Lifyorli's early launch has been successful, with over 200 physicians prescribing it within the first month. The drug's inclusion in NCCN guidelines as a preferred regimen is expected to enhance adoption.
- Challenges in Revenue Recognition — Management pointed out that revenue often dips in Q1 due to insurance reauthorization procedures that disrupt patient coverage. Sean Maduck explained, "the full revenue impact of patients added this quarter will grow sub...
Read the full Corcept Therapeutics Incorporated transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 28 calls on record spanning February 20, 2020 to July 29, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 Corcept Therapeutics Incorporated earnings call transcripts on record, spanning February 20, 2020 to July 29, 2026. Based on this history, Corcept Therapeutics Incorporated reports quarterly. The most recent call on file is dated July 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CORT
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 28
- First call
- February 20, 2020
- Most recent
- July 29, 2026
- Reporting cadence
- quarterly